Preferred Label : Allogeneic TCRa/b-depleted HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified
RQR8-expressing T Cells BSB-1001;
NCIt synonyms : Allogeneic Anti-miHA-1 TCR Lentivector Transduced T-cells BSB-1001; Allogeneic Anti-HA-1 TCR-engineered T-cells BSB-1001; Allogeneic HA-1-targeting TCR T-cells BSB-1001; Allogeneic miHA-reactive TCR-modified T-cells BSB-1001; T-cell Receptor Engineered Donor T-Cells BSB-1001; Allogeneic Anti-HA-1 T-cell BSB-1001;
NCIt definition : A preparation of T-cell receptor (TCR) alpha and beta (TCRa/b)-depleted donor-derived
T-lymphocytes that have been transduced with a lentivirus vector encoding a TCR specific
for HLA-A*02:01-restricted minor histocompatibility antigen HA-1 (HA1) and expressing
RQR8, with potential immunomodulating and antineoplastic activities. Following HLA-matched
allogeneic hematopoietic cell transplantation (HCT) in HLA-A*02:01 positive patients,
allogeneic TCRa/b-depleted HA-1 minor histocompatibility antigen-reactive TCR-modified
RQR8-expressing T cells BSB-1001 specifically recognize and bind to HA-1 expressed
on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination
of tumor cells expressing HLA-A*02:01 HA-1. HA-1 is a lineage-specific antigen found
on leukemia cells. BSB-1001 carries the universal RQR8 safety off switch, which allows
selective removal of the T-cells through both complement-dependent cytotoxicity (CDC)
and antibody-dependent cellular cytotoxicity (ADCC) following administration of rituximab
if unacceptable side-effects occur. CRISPR-cas9 editing of the donor T-cells deletes
the endogenous TCRa/b chains. Depletion of TCRa/b increases expression of the transduced
TCR and reduces risk of graft-versus-host disease (GVHD) caused by native TCRs.;
Molecule name : BSB 1001; BSB-1001;
Origin ID : C212124;
concept_is_in_subset
- has_target
